Biobank for multidrug-resistant tuberculosis research: Importance of sequential samples

2021 ◽  
Author(s):  
Yoohyun Hwang ◽  
Jiyeon Kim ◽  
Seungkyu Park ◽  
Sungweon Ryoo
Keyword(s):  
International Research ◽  
Multidrug Resistant ◽  
Tuberculosis Patients ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
National Tuberculosis ◽  
Sequential Samples ◽  
Resistant Strains

Abstract Since 2013, Masan National Tuberculosis Hospital has collected standardized specimens from its tuberculosis patients, which include a large number of multidrug-resistant strains. The repository collects matched participants and their bacilli samples, compiling sequential samples from the beginning of treatment. The repository aims to provide resources for in-depth international research.

scholarly journals Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients

2012 ◽  
Vol 102 (6) ◽  
pp. 363 ◽  
Author(s):  
Tashneem Harris ◽  
Soraya Bardien ◽  
H Simon Schaaf ◽  
Lucretia Petersen ◽  
Greetje De Jong ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Multidrug Resistant ◽  
Hiv Positive ◽  
Tuberculosis Patients ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Hiv Negative

scholarly journals Pretreatment Out-of-Pocket Expenses for Presumptive Multidrug-Resistant Tuberculosis Patients, India, 2016–2017

2020 ◽  
Vol 26 (5) ◽  
pp. 989-992
Author(s):  
Priya Rathi ◽  
Kalpita Shringarpure ◽  
Bhaskaran Unnikrishnan ◽  
Vineet Kumar Chadha ◽  
Vishak Acharya ◽  
...  
Keyword(s):  
Multidrug Resistant ◽  
Tuberculosis Patients ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Out Of Pocket Expenses

Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis

2019 ◽  
Vol 71 (2) ◽  
pp. 415-418 ◽  
Author(s):  
Kwonjune J Seung ◽  
Palwasha Khan ◽  
Molly F Franke ◽  
Saman Ahmed ◽  
Stalbek Aiylchiev ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Observational Study ◽  
Multidrug Resistant ◽  
Sputum Culture ◽  
Drug Markets ◽  
Sputum Culture Conversion ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Resistant Strains ◽  
Culture Conversion

Abstract Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765.

Sign in / Sign up

Export Citation Format

Share Document